Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Yunyi Kang
Identification of Drug Combinations Containing Imatinib for Treatment of BCR-ABL+ Leukemias
PLoS ONE
Multidisciplinary
Combinations of Kinase Inhibitors Protecting Myoblasts Against Hypoxia
PLoS ONE
Multidisciplinary
Related publications
A Non-Atp-Competitive Inhibitor of BCR-ABL Overrides Imatinib Resistance
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
In Vivo Imaging of BCR-Abl Overexpressing Tumors With a Radiolabeled Imatinib Analog as an Imaging Surrogate for Imatinib
Journal of Nuclear Medicine
Medicine
Nuclear Medicine
Radiology
Imaging
Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia
Cancer Research
Cancer Research
Oncology
NPB001-05 Inhibits BCR-Abl Kinase Leading to Apoptosis of Imatinib-Resistant Cells
Frontiers in Bioscience - Elite
Immunology
Molecular Biology
Biochemistry
Microbiology
Medicine
Genetics
ON012380: A Non-Atp Competitive Inhibitor of BCR-ABL for the Therapy of Imatinib-Resistant CMLs
Semi‑random Mutagenesis Profile of BCR‑ABL During Imatinib Resistance Acquirement in K562 Cells
Molecular Medicine Reports
Oncology
Genetics
Molecular Biology
Biochemistry
Cancer Research
Molecular Medicine
Simultaneous Targeting of Aurora Kinases and BCR-Abl Kinase by the Small Molecule Inhibitor PHA-739358 Is Effective Against Imatinib-Resistant BCR-ABL Mutations Including T315I
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Coexistence of AML1/RUNX1 and BCR-ABL Point Mutations in an Imatinib-Resistant Form of CML
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
In Vitro and in Vivo Activity of SKI-606, a Novel SRC-Abl Inhibitor, Against Imatinib-Resistant BCR-Abl+ Neoplastic Cells
Cancer Research
Cancer Research
Oncology
